US4678609A - Process for the preparation of corticosteroid-21-phosphoric acids and their salts and the corticosteroid-21-phosphoric acid triesters - Google Patents
Process for the preparation of corticosteroid-21-phosphoric acids and their salts and the corticosteroid-21-phosphoric acid triesters Download PDFInfo
- Publication number
- US4678609A US4678609A US06/795,542 US79554285A US4678609A US 4678609 A US4678609 A US 4678609A US 79554285 A US79554285 A US 79554285A US 4678609 A US4678609 A US 4678609A
- Authority
- US
- United States
- Prior art keywords
- denotes
- corticosteroid
- formula
- alkyl
- phosphoric acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
Definitions
- the present invention relates to a process for the preparation of corticosteroid-21-phosphoric acids and pharmaceutically active salts thereof, in particular methylprednisolone disodium phosphate, and to the corticosteroid-21-phosphoric acid triesters.
- Steroid 21-phosphates and pharmaceutically active salts thereof are disclosed in Japanese Published Application No. 41-12,351, U.S. Pat. No. 2,932,657, German Offenlegungsschrift No. 2,225,658 and British Pat. No. 1,010,031. It is a serious disadvantage of the known processes of preparation that, for example, an appreciable proportion of phosphoric acid diester is formed and that, because of the reaction conditions (excess of phosphate), it is very difficult to prepare a steroid phosphate free from extraneous salts.
- the object of the invention is, therefore, to prepare corticosteroid-21-phosphoric acids and pharmaceutically active salts thereof in a simple manner and in a highly pure form.
- V denotes H, OH, O or halogen
- W denotes H or OH
- Y denotes H or F
- X represents OH or halogen
- organic phosphoric acid ester of the formula IVa or IVb ##STR7## in which Z is C 1 -C 8 -alkyl, preferably C 1 -C 4 -alkyl, which can be substituted in the ⁇ -position by phenyl which can in turn be substituted by Cl, Br, CN or NO 2 , it being possible for alkyl radicals having at least 2 carbon atoms to be monosubstituted in the ⁇ -position by CN, nitrophenyl or SO 2 --C1--4 - alkyl or to be disubstituted or trisubstituted by Cl and/or Br, and
- Hal is halogen, preferably Cl or Br, and
- R denotes C 1 -C 8 -alkyl, but one radical R can also be benzyl and/or hydrogen,
- the substituents are preferably in the o-position or p-position.
- Processes which have proved particularly suitable for the preparation of the compounds II are those in which a compound of the formula I in which X denotes hydroxyl is reacted with a compound IV in which Hal denotes chlorine.
- a process in which Z denotes tert.-butyl is also preferred in many cases.
- the saponification of the compounds II can be effected by means of acids or bases. In many cases it is carried out particularly advantageously by means of acids which have a pK value less than 3, preferably hydrochloric acid or trifluoroacetic acid.
- halogen denotes fluorine, chlorine, bromine or iodine.
- the process according to the invention embraces, for example, the following embodiments: the reaction of a hydroxycorticosteroid, in particular 6 ⁇ -methylprednisolone with an organic phosphoric acid diester-chloride, for example ditert.-butylphosphoric acid chloride, in the presence of a base, for example pyridine.
- a base for example pyridine.
- 21-iodoprednisolone can be used as the starting material and reacted with an alkylammonium salt of an organic phosphoric acid diester in an inert solvent, such as methylene chloride, acetonitrile or an ether, such as dimethoxyethane.
- the resulting corticosteroid-phosphoric acid triester After being extracted into an organic solvent, for example methylene chloride, the resulting corticosteroid-phosphoric acid triester is washed with water and, after the organic phase has been dried, is crystallized out and thus separated from water-soluble impurities and other organic impurities.
- organic solvent for example methylene chloride
- the new steroid-phosphoric acid triester II is converted into the corticosteroid-phosphoric acid monoester by means of an acid, for example HCl or trifluoroacetic acid, preferably in an inert solvent, such as chloroform, halogenated hydrocarbons or methylene chloride, at room temperature.
- an acid for example HCl or trifluoroacetic acid
- an inert solvent such as chloroform, halogenated hydrocarbons or methylene chloride
- partitioning is carried out between (a) an organic phase, such as, initially, methylene chloride and then, for example, n-butanol or n-hexanol, and (b) water.
- the pH of the solution is then rendered slightly alkaline in the organic phase by titration with a base, preferably sodium hydroxide solution, and the disodium salt, for example, is thus obtained.
- a base preferably sodium hydroxide solution
- the resulting steroid 21-phosphate can be obtained in a solid form either by evaporation or by freeze-drying the aqueous solution, if desired after further purification with active charcoal.
- cortisol cortisone
- prednisolone 6 ⁇ -F-prednisolone
- dexamethasone dexamethasone
- betamethasone desoximetasone
- 6 ⁇ -methylprednisolone 6 ⁇ -methylprednisolone
- the invention also relates to the new compounds of the formula II obtained in the first stage.
- IR (KBr): ⁇ 2980, 2930, 1740, 1650, 1610, 1370, 1260, 1000 cm -1 .
- UV (methanol): ⁇ 260 16000 lxmol -1 xcm -1 .
- the aqueous phase was separated off and washed again with diethyl ether, and the disodium salt of 6 ⁇ -methylprednisolone 21-phosphate was obtained as a colorless powder by freeze-drying. It was identical with the product from Example 5.
Abstract
Steroid-21-phosphoric acids and pharmaceutically usable salts thereof of the formula III ##STR1## (in which U=H or CH3, V=H, OH, O or Hal; W=H or OH and Y=H or F) are obtained in a very pure state by reacting I ##STR2## (in which X=OH or Hal) with an organic phosphoric acid ester of the formula IVa or IVb ##STR3## (in which Z=optionally substituted alkyl and R=alkyl). The compounds II ##STR4## obtained thereby is saponified to give III and the latter, if appropriate, is neutralized to give the salt. Compounds II are new.
Description
The present invention relates to a process for the preparation of corticosteroid-21-phosphoric acids and pharmaceutically active salts thereof, in particular methylprednisolone disodium phosphate, and to the corticosteroid-21-phosphoric acid triesters.
Steroid 21-phosphates and pharmaceutically active salts thereof are disclosed in Japanese Published Application No. 41-12,351, U.S. Pat. No. 2,932,657, German Offenlegungsschrift No. 2,225,658 and British Pat. No. 1,010,031. It is a serious disadvantage of the known processes of preparation that, for example, an appreciable proportion of phosphoric acid diester is formed and that, because of the reaction conditions (excess of phosphate), it is very difficult to prepare a steroid phosphate free from extraneous salts.
The object of the invention is, therefore, to prepare corticosteroid-21-phosphoric acids and pharmaceutically active salts thereof in a simple manner and in a highly pure form.
Surprisingly, it has been possible to prepare these compounds of the formula III ##STR5## in which U denotes H or CH3,
V denotes H, OH, O or halogen,
W denotes H or OH and
Y denotes H or F,
or pharmaceutically active salts thereof, by reacting a corticosteroid of the formula I ##STR6## in which U, V, W and Y have the meaning indicated and
X represents OH or halogen,
with an organic phosphoric acid ester of the formula IVa or IVb ##STR7## in which Z is C1 -C8 -alkyl, preferably C1 -C4 -alkyl, which can be substituted in the α-position by phenyl which can in turn be substituted by Cl, Br, CN or NO2, it being possible for alkyl radicals having at least 2 carbon atoms to be monosubstituted in the β-position by CN, nitrophenyl or SO2 --C1--4- alkyl or to be disubstituted or trisubstituted by Cl and/or Br, and
Hal is halogen, preferably Cl or Br, and
R denotes C1 -C8 -alkyl, but one radical R can also be benzyl and/or hydrogen,
and thus preparing a new compound of the formula II ##STR8## in which U, V, W, Y and Z have the meanings mentioned, and saponifying this compound II to give the compound III and, if appropriate, neutralizing the latter to give the salt.
If Z contains substituted phenyl radicals, the substituents are preferably in the o-position or p-position.
Processes which have proved particularly suitable for the preparation of the compounds II are those in which a compound of the formula I in which X denotes hydroxyl is reacted with a compound IV in which Hal denotes chlorine. A process in which Z denotes tert.-butyl is also preferred in many cases. A process in which a compound of the formula I in which X=Br or I is reacted with a (C1 -C8)-alkylammonium or aralkylammonium salt of a (C1 -C4)-dialkylphosphoric acid is also preferred.
The saponification of the compounds II can be effected by means of acids or bases. In many cases it is carried out particularly advantageously by means of acids which have a pK value less than 3, preferably hydrochloric acid or trifluoroacetic acid.
Unless there is an express indication to the contrary, halogen denotes fluorine, chlorine, bromine or iodine.
The process according to the invention embraces, for example, the following embodiments: the reaction of a hydroxycorticosteroid, in particular 6α-methylprednisolone with an organic phosphoric acid diester-chloride, for example ditert.-butylphosphoric acid chloride, in the presence of a base, for example pyridine. Alternatively, 21-iodoprednisolone can be used as the starting material and reacted with an alkylammonium salt of an organic phosphoric acid diester in an inert solvent, such as methylene chloride, acetonitrile or an ether, such as dimethoxyethane. After being extracted into an organic solvent, for example methylene chloride, the resulting corticosteroid-phosphoric acid triester is washed with water and, after the organic phase has been dried, is crystallized out and thus separated from water-soluble impurities and other organic impurities.
In the next stage, the new steroid-phosphoric acid triester II is converted into the corticosteroid-phosphoric acid monoester by means of an acid, for example HCl or trifluoroacetic acid, preferably in an inert solvent, such as chloroform, halogenated hydrocarbons or methylene chloride, at room temperature. The yields decrease at temperatures above 40° C., since the steroid skeleton becomes increasingly unstable. In this process the corticosteroid-phosphate obtained is already in a very good state of purity. The saponification of the steroid-phosphoric acid triester to give the steroid-phosphoric acid monoester can also be carried out under alkaline conditions, if the steroid radical is not alkali-sensitive. After the removal of the solvent and the excess acid, partitioning is carried out between (a) an organic phase, such as, initially, methylene chloride and then, for example, n-butanol or n-hexanol, and (b) water. The pH of the solution is then rendered slightly alkaline in the organic phase by titration with a base, preferably sodium hydroxide solution, and the disodium salt, for example, is thus obtained. In the course of this the disodium salt passes over into the aqueous phase, and the last organic impurities remain in the organic phase.
The resulting steroid 21-phosphate can be obtained in a solid form either by evaporation or by freeze-drying the aqueous solution, if desired after further purification with active charcoal.
Starting corticosteroids of particular interest are cortisol, cortisone, prednisolone, 6α-F-prednisolone, dexamethasone, betamethasone, desoximetasone, 6α-methylprednisolone and the like.
The invention also relates to the new compounds of the formula II obtained in the first stage.
(1A) 10 g of ditertiary-butylphosphoric acid chloride, dissolved in 30 ml of methylene chloride, were added, at -40° C. and in the course of 20 minutes, to 7.5 g of 6α-methylprednisolone, dissolved in 35 ml of anhydrous pyridine and 8 ml of triethylamine. The reaction was carried out for 40-60 hours at -20° C. After the solvent had been removed, the residue was partitioned between 120 ml of methylene chloride and 40 ml of water. When the organic phase had been washed with water and dried with sodium sulfate, the resulting oil was induced to crystallize by means of ethyl acetate. This gave 7.8 g of the new ditertiary-butyl ester of melting point 153° C. (decomposition)
[αD ]23 =+70.8° C,H,P calculated C 63.6 H 8.3 P 5.4% found C 63.2 H 8.3 P 5.2%.
31 P-NMR (d6 DMSO) re. 85% H3 PO4 ε=8.9 ppm
IR (KBr): ν=2980, 2930, 1740, 1650, 1610, 1370, 1260, 1000 cm-1.
1 H-NMR: (CDCl3 /TMS) δ=1.5 ppm [C-(CH3)3 ]
(1B) 9.7 g of 21-iodo-6α-methylprednisolone and 15 g of tetra-n-butylammonium bis-tertiary-butyl phosphate were dissolved in 150 ml of acid-free methylene chloride, and the solution was stirred for 20 hours at room temperature. The reaction mixture was then washed with water, a 2% strength thiosulfate solution and then with water and was dried. After the removal of the methylene chloride, the 6α-methylprednisolone-21-phosphoric acid bis-tertiary-butyl ester crystallized from ethyl acetate; 11 g of melting point 150°-152° C. (decomposition). For analytical data see Example 1A.
(1C) 5.3 g of 21-iodo-6α-methylprednisolone and 9 g of benzyltriethylammonium ditertiary-butyl-phosphate were dissolved in 135 ml of dimethoxyethane, and the solution was stirred at room temperature for 40 hours with the exclusion of light. After the solvent had been removed, the residue was partitioned between methylene chloride and water, and the organic phase was washed with thiosulfate and dried with sodium sulfate. The 6 bis-tertiary-butyl α-methylprednisolone-21-phosphoric acid ester was induced to crystallize by means of ethyl acetate, 5.4 g having analytical data identical with those of Example 1A and 1B.
(2) 1.7 g of phosphoric acid dimethyl ester-chloride, dissolved in 25 ml of methylene chloride, were added, at 0° C. and in the course of 30 minutes, to 3.7 g of 6α-methylprednisolone, dissolved in 35 ml of anhydrous pyridine. The reaction was complete after 18 hours at room temperature; the pyridine was removed under reduced pressure. The residue was partitioned between methylene chloride and water (pH 3), and the organic phase was washed with water until neutral and dried with Na2 SO4. After the removal of the solvent, the new 6α-methylprednisolone-21-phosphoric acid bis-methylester left as residue (3.1 g) was recrystallized from 8:1 dioxane/dimethylformamide. Melting point 245°-46° C. (decomposition).
31 P-NMR (d6 DMSO) rel. 85% H3 PO4 δ=2.3 ppm
1 H-NMR (d6 DMSO) δ=3.62 (doublet) ppm (P-OCH3)
(3) 6.0 g of bis-2,2,2-trichloroethylphosphoric acid chloride were added at room temperature to 3.7 g of 6α-methylprednisolone, dissolved in 42 ml of anhydrous pyridine. The reaction mixture was worked up after 20 hours, the pyridine was removed by distillation under reduced pressure, the residue was partitioned between methylene chloride and water (pH 2), then washed with water until neutral and and the organic phase was dried with Na2 SO4. This gave 1.6 g of the new 6α-methylprednisolone-21-phosphoric acid bis-2,2,2-trichloroethylester in the form of colorless crystals of melting point 216°-217° C. 31 P-NMR (d6 DMSO) re. 85% H3 PO4 δ=9.4 ppm
(4) 6.3 g of bis-4-nitrophenylethylphosphoric acid chloride were added at 0° C. to 3.7 g of 6α-methylprednisolone in 40 ml of anhydrous pyridine; the mixture was kept at 0° C. for 2 hours and allowed to stand at room temperature for a further 3 hours. After the removal of the pyridine, the residue was partitioned between methylene chloride and water (pH 3), and the organic phase was rinsed with water and dried with Na2 SO4. The crude product was purified by chromatography over 300 g of silica gel, using 3% methanol in methylene chloride as the mobile phase. The new 6α-methylprednisolone-21-phosphoric acid bis-4-nitrophenylethyl ester (5.7 g) crystallized from 4:1 toluene/diethyl ether. Melting point 174°-176° C.
UV (methanol): ε260 =16000 lxmol-1 xcm-1.
(5) 10.8 g of the ester prepared in accordance with 1A, 1B or 1C were dissolved in 190 ml of chloroform, 10.8 g (7.35 ml) of trifluoroacetic acid were added and the mixture was stirred at room temperature for 20 hours. The solvent and the trifluoroacetic acid were removed under reduced pressure, if necessary with the aid of toluene. The residue was partitioned between distilled water and chloroform and then between water and n-hexanol. The steroid phosphate was then in the n-hexanol. A layer of fresh distilled water was placed below the n-hexanol phase, and the mixture was then titrated carefully with 1 N sodium hydroxide solution to pH 8.6. The aqueous phase was then separated off and washed again with diethyl ether, and the disodium salt of 6α-methylprednisolone-21-phosphoric acid was obtained as a colorless powder by freeze-drying.
[αD ]24 =84° (H2 O) 31 P-NMR (D2 O) δ=3.5 ppm
UV: ε243 =126000 lxmol-1 xcm-1.
(6) 7.5 g of 6α-methylprednisolone-21-phosphoric acid bis-4-nitrophenylethyl ester according to Example 4 were dissolved at room temperature in 500 ml of diazabicycloundecene in pyridine (0.5 molar), and the mixture was stirred for 40 hours. After the removal of the solvent, the residue was partitioned between methylene chloride and water; the organic extracts were discarded. The pH of the solution was then adjusted to 1 with hydrochloric acid, and the product was extracted into n-butanol or nhexanol. The layer of distilled water was placed under the butanol or hexanol phase, and the mixture was then titrated to pH 8.5 with 1 N NaOH. The aqueous phase was separated off and washed again with diethyl ether, and the disodium salt of 6α-methylprednisolone 21-phosphate was obtained as a colorless powder by freeze-drying. It was identical with the product from Example 5.
Claims (4)
1. A process for the preparation of corticosteroid-21-phosphoric acids of the general formula III ##STR9## and of pharmaceutically active salts thereof, in which formula III U denotes H or CH3,
V denotes H, OH, O or halogen,
W denotes H or OH and
Y denotes H or F,
which comprises reacting a corticosteroid of the formula I ##STR10## in which U, V, W and Y have the meaning indicated and X represents OH or halogen, with an organic phosphoric acid ester of the formula IVa or IVb ##STR11## in which Z is C1-8 -alkyl which is unsubstituted or substituted in the α-position by phenyl which in turn is unsubstituted or substituted by Cl, Br, CN or NO2, alkyl radicals having at least 2 carbon atoms being unsubstituted or monosubstituted in the β-position by CN, nitrophenyl or SO2 --C1-4 -alkyl or disubstituted or trisubstituted by Cl and/or Br, and
Hal denotes halogen and
R denotes C1-8 -alkyl, but a radical R can also be benzyl and/or hydrogen,
and thus preparing a compound of the formula II ##STR12## in which U, V, W, Y and Z have the meanings mentioned, and saponifying this compound II to give the compound III and, if appropriate, neutralizing the latter to give the salt.
2. The process as claimed in claim 1, wherein X denotes hydroxyl and Hal denotes chlorine.
3. The process as claimed in claim 1, wherein X denotes bromine or iodine and wherein the compound of the formula I is reacted with a (C1 -C8)-alkylammonium or aralkylammonium salt of a (C1 -C4)-dialkylphosphoric acid.
4. The process as claimed in claim 1,
wherein the saponification is carried out by means of an acid having a phK value of less than 3.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE3440794 | 1984-11-08 | ||
DE19843440794 DE3440794A1 (en) | 1984-11-08 | 1984-11-08 | METHOD FOR PRODUCING CORTICOSTEROID-21 PHOSPHORIC ACIDS AND THEIR SALTS, AND THE CORTICOSTEROID-21 PHOSPHORIC ACID RETRIESTER |
Publications (1)
Publication Number | Publication Date |
---|---|
US4678609A true US4678609A (en) | 1987-07-07 |
Family
ID=6249784
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US06/795,542 Expired - Fee Related US4678609A (en) | 1984-11-08 | 1985-11-06 | Process for the preparation of corticosteroid-21-phosphoric acids and their salts and the corticosteroid-21-phosphoric acid triesters |
Country Status (8)
Country | Link |
---|---|
US (1) | US4678609A (en) |
EP (1) | EP0181561A1 (en) |
JP (1) | JPS61115095A (en) |
DE (1) | DE3440794A1 (en) |
DK (1) | DK514085A (en) |
ES (2) | ES8704970A1 (en) |
GR (1) | GR852694B (en) |
PT (1) | PT81443B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4879379A (en) * | 1986-09-19 | 1989-11-07 | Yoshinori Kidani | Novel platinum-steroid complexes |
US4898693A (en) * | 1986-11-28 | 1990-02-06 | Schering Aktiengesellschaft | Process for production of 6α,9α-difluoro-11β,17α-dihydroxy-16α-methyl-4-pregnene-3,20-dione and its derivatives |
US5192755A (en) * | 1986-01-15 | 1993-03-09 | Akzo N.V. | Pregnane derivatives as immunomodulators |
US20040157810A1 (en) * | 2002-08-23 | 2004-08-12 | Teicher Martin H. | Corticosteroid conjugates and uses thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6494447B2 (en) | 2000-06-13 | 2002-12-17 | Giesecke & Devrient America, Inc. | Stacker wheel control apparatus and method utilizing start-stop synchronization |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2870177A (en) * | 1954-08-04 | 1959-01-20 | Merck & Co Inc | delta4-11-oxygenated-pregnene-17alpha, 21-diol-3, 20-dione 21-phosphate and salts thereof |
US3048581A (en) * | 1960-04-25 | 1962-08-07 | Olin Mathieson | Acetals and ketals of 16, 17-dihydroxy steroids |
US3053834A (en) * | 1961-01-26 | 1962-09-11 | Olin Mathieson | 21-phosphates of steroid acetals and ketals |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3248408A (en) * | 1963-07-22 | 1966-04-26 | Merck & Co Inc | Purification of steroid phosphates |
GB1010031A (en) * | 1963-09-24 | 1965-11-17 | Upjohn Co | Improvements in or relating to the preparation of steroids |
-
1984
- 1984-11-08 DE DE19843440794 patent/DE3440794A1/en not_active Withdrawn
-
1985
- 1985-10-29 EP EP85113776A patent/EP0181561A1/en not_active Withdrawn
- 1985-11-06 ES ES548569A patent/ES8704970A1/en not_active Expired
- 1985-11-06 US US06/795,542 patent/US4678609A/en not_active Expired - Fee Related
- 1985-11-07 GR GR852694A patent/GR852694B/el unknown
- 1985-11-07 DK DK514085A patent/DK514085A/en not_active Application Discontinuation
- 1985-11-07 JP JP60248151A patent/JPS61115095A/en active Pending
- 1985-11-07 PT PT81443A patent/PT81443B/en unknown
-
1986
- 1986-05-14 ES ES554953A patent/ES8704971A1/en not_active Expired
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2870177A (en) * | 1954-08-04 | 1959-01-20 | Merck & Co Inc | delta4-11-oxygenated-pregnene-17alpha, 21-diol-3, 20-dione 21-phosphate and salts thereof |
US3048581A (en) * | 1960-04-25 | 1962-08-07 | Olin Mathieson | Acetals and ketals of 16, 17-dihydroxy steroids |
US3053834A (en) * | 1961-01-26 | 1962-09-11 | Olin Mathieson | 21-phosphates of steroid acetals and ketals |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5192755A (en) * | 1986-01-15 | 1993-03-09 | Akzo N.V. | Pregnane derivatives as immunomodulators |
US4879379A (en) * | 1986-09-19 | 1989-11-07 | Yoshinori Kidani | Novel platinum-steroid complexes |
US4898693A (en) * | 1986-11-28 | 1990-02-06 | Schering Aktiengesellschaft | Process for production of 6α,9α-difluoro-11β,17α-dihydroxy-16α-methyl-4-pregnene-3,20-dione and its derivatives |
US20040157810A1 (en) * | 2002-08-23 | 2004-08-12 | Teicher Martin H. | Corticosteroid conjugates and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
ES8704970A1 (en) | 1987-04-16 |
ES8704971A1 (en) | 1987-04-16 |
GR852694B (en) | 1986-03-10 |
DK514085A (en) | 1986-05-09 |
DE3440794A1 (en) | 1986-05-15 |
PT81443B (en) | 1987-07-02 |
EP0181561A1 (en) | 1986-05-21 |
PT81443A (en) | 1985-12-01 |
JPS61115095A (en) | 1986-06-02 |
ES548569A0 (en) | 1987-04-16 |
ES554953A0 (en) | 1987-04-16 |
DK514085D0 (en) | 1985-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL119050B1 (en) | Process for preparing corticosteroid derivatives | |
EP0081674B1 (en) | Intermediate products, process for preparing them and a process for the preparation of cephalosporins | |
US4678609A (en) | Process for the preparation of corticosteroid-21-phosphoric acids and their salts and the corticosteroid-21-phosphoric acid triesters | |
EP0038614A2 (en) | Esters of 5- and 6-oxo-prostaglandins | |
KR0132570B1 (en) | Method of the systhesis of 6-methylene derivatives of androsta-1,4-diene-3,17-dione | |
US4552869A (en) | O-Alkyl-O-carbamoylglycerophosphocholines and the use for treating hypertension | |
US2950298A (en) | Steroid secondary 21-phosphate esters | |
US5159091A (en) | Process for preparing 21-desoxyprednisolone 17-esters | |
US4386079A (en) | Method of treating depression | |
KR970005316B1 (en) | 21-alkoxy steroid compounds | |
EP0019111A1 (en) | Process for the preparation of phosphonomaleic acid esters | |
CZ191398A3 (en) | Process for preparing 9,11{beta}epoxy-steroids | |
HU180951B (en) | Process for preparing acyl derivatives of steroid-21-thiols | |
US4242511A (en) | Production of amine salts of acid O,S-dialkylthiophosphoric acid | |
PL191606B1 (en) | Method of obtaining 3-cyano-2,4-dichlorogeno-5-fluorobenzoic acids | |
IE58798B1 (en) | Process for the production of 17 alpha-ethynyl-17-hydr oxy-18-methyl-4, 15-estradien-3-one, and the novel starting compounds for this process | |
US5250711A (en) | Amine salts of alkane-1,n-dicarboxylic acid mono-(2-sulfato-ethyl) amides | |
EP0374166B1 (en) | Amine salts of alkane-1,n-dicarboxylic acid mono-(2-sulfato-ethyl)amides | |
EP0127217B1 (en) | New process for the preparation of 20-keto-delta16-steroids and new intermediate compounds formed in this process | |
US4457873A (en) | Process for preparing phosphonomethylated amino acids | |
HU182775B (en) | Process for preparing new 3-chloro-pregnane derivatives | |
US4681943A (en) | 1-acyl-1-(2-pyridinyl)semicarbazides | |
US4531004A (en) | Dimetronidazole phosphates | |
US5332847A (en) | Process for the preparation of 21-bromo-4-pregnene-3,20-dione derivatives | |
US4946959A (en) | Method of preparing 5-alkyl-1-(2-pyridinyl)-1H-1,2,4-triazol-3-ols |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: HOECHST AKTIENGESELLSCHAFT, D-6230 FRANKFURT AM MA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:ENGELS, JOACHIM;REEL/FRAME:004481/0395 Effective date: 19851008 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 19910707 |